SECTOR:

Diagnostics, Therapeutics, Medtech, HC Services

FUND/VEHICLE:

NFLS Fund & Core Investment

INVESTMENT DATE:

2015

GEOGRAPHY:

China, US

STATUS CURRENT/FORMER INVESTMENT:

Existing

WEBSITE:

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.